Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Spira 80-marker panel for lung cancer

Spira 80-marker panel for lung cancer



QA State: Curated
Short Name:
HGNC Name:

This 80-gene biomarker panel is used to distinguish smokers with lung cancer from smokers without lung cancer. The biomarker panel had approximately 90% sensitivity for stage 1 cancer across all subjects. Adding cytopathology data gives 95% sensitivity and 95% negative predictive value. (7 of the 80 biomarker probesets had no annotated gene symbol associated with them.) List of genes in the panel: DMD, NELL2, FGF14, TMEM47, ANXA3, PLA2G4A, DNAJC12, SLC39A8, DEFB1, PPBP, C6, FCGR3A, IL8, SERPINA1, CXCL2, RGS1, DUSP6, TOB1, FOS, SOX9, CD55, CD55, SLC4A4, CD164, ATP6AP2, ARL6IP5, CCT2, UBXD2, RAB1A, TRAM1, TMED2, YWHAE, C1orf80, TPD52, ACTR2, CPNE3, PTK9, UBE2J1, FXR1, SPN, PPP2CA, AD7C-NTP, STARD7, KIAA0738, RPL35A, GTF2H3, ZNF611, LOC152719, PRR11, ZC3H7B, ZNF354A, UBE2D2, ZNF160, FBXW12, ALMS1, ATP8B1, BACH2, TSR1, HDGF2, FLJ14346, LOC653471, DCLRE1C, DUOX1, LOC153561, DKFZP434A0131, GLT28D1, SENP6, FTO, LMO4, CCDC81, COX5B, FTL, NUCKS1

Panel Details

No member markers defined for this panel.


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Curated


Gene expression in histologically normal large-airway epithelial cells in smokers with the suspicion of lung cancer was studied to determine if a lung cancer biomarker could be developed. Samples were obtained at bronchoscopy and divided into a training set and a testing set. Results showed that gene expression in cytologically normal large-airway epithelial cells can serve as a lung cancer biomarker. This panel biomarker is currently being verified for its application for nasal epithelium.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated resources found.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.